Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma

NCT06733441 is registered in ClinicalTrials.gov with Treeline Biosciences, Inc. as lead sponsor.

NCT NCT06733441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06733441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma
Lead sponsor
Treeline Biosciences, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 16, 2024
Completion date
November 15, 2028
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma